AAPL316.22-3.75 (-1.17%) ▼|ABBV248.78-7.68 (-2.99%) ▼|ABT105.04-0.54 (-0.51%) ▼|ACN179.19+0.15 (+0.08%) ▲|ADBE257.55+0.29 (+0.11%) ▲|AMAT473.00+0.21 (+0.04%) ▲|AMD514.91+9.17 (+1.81%) ▲|AMGN390.88-2.29 (-0.58%) ▼|AMT175.45-0.30 (-0.17%) ▼|AMZN252.84-4.13 (-1.61%) ▼|AVGO364.32-4.24 (-1.15%) ▼|AXP322.50-3.62 (-1.11%) ▼|BA211.19+0.36 (+0.17%) ▲|BAC61.83-0.56 (-0.90%) ▼|BKNG173.01-7.30 (-4.05%) ▼|BLK1,088.81-7.02 (-0.64%) ▼|BMY64.44-0.26 (-0.40%) ▼|BNY161.52-1.35 (-0.83%) ▼|BRK-B502.72-3.10 (-0.61%) ▼|C135.65-1.13 (-0.82%) ▼|CAT825.99+3.46 (+0.42%) ▲|CL87.45-0.96 (-1.09%) ▼|CMCSA26.06-0.27 (-1.03%) ▼|COF212.80-1.23 (-0.57%) ▼|COP136.61+1.56 (+1.16%) ▲|COST902.98-7.20 (-0.79%) ▼|CRM251.15+1.97 (+0.79%) ▲|CSCO109.96+0.79 (+0.72%) ▲|CVS96.34+0.25 (+0.26%) ▲|CVX213.35+3.35 (+1.60%) ▲|DE684.82+4.02 (+0.59%) ▲|DHR202.86-2.33 (-1.13%) ▼|DIS103.47-1.63 (-1.55%) ▼|DUK121.40+0.15 (+0.12%) ▲|EMR151.94-0.24 (-0.16%) ▼|FDX310.75-3.36 (-1.07%) ▼|GD356.58+0.03 (+0.01%) ▲|GE329.16-5.78 (-1.73%) ▼|GEV982.00+10.62 (+1.09%) ▲|GILD145.73-0.92 (-0.62%) ▼|GM85.56-0.22 (-0.26%) ▼|GOOG327.29-8.09 (-2.41%) ▼|GOOGL329.68-8.69 (-2.57%) ▼|GS1,017.52-19.16 (-1.85%) ▼|HD311.06-2.61 (-0.83%) ▼|HON208.03-0.21 (-0.10%) ▼|IBM235.36+3.25 (+1.40%) ▲|INTC103.88-0.59 (-0.56%) ▼|INTU320.05+1.12 (+0.35%) ▲|ISRG353.50+3.34 (+0.95%) ▲|JNJ268.79-0.39 (-0.14%) ▼|JPM351.52-2.03 (-0.57%) ▼|KO87.77-0.66 (-0.74%) ▼|LIN467.79-0.59 (-0.13%) ▼|LLY1,131.65+7.79 (+0.69%) ▲|LMT538.72+2.40 (+0.45%) ▲|LOW199.94-0.88 (-0.44%) ▼|LRCX320.58+0.16 (+0.05%) ▲|MA566.56-4.38 (-0.77%) ▼|MCD253.85-1.99 (-0.78%) ▼|MDLZ61.01-0.62 (-1.01%) ▼|MDT92.18-0.22 (-0.23%) ▼|META643.68+30.20 (+4.92%) ▲|MMM166.19-1.33 (-0.79%) ▼|MO67.57-0.61 (-0.89%) ▼|MRK148.14-0.34 (-0.23%) ▼|MS213.88-2.43 (-1.12%) ▼|MSFT492.73-1.22 (-0.25%) ▼|MU1,001.54+1.28 (+0.13%) ▲|NEE84.19+0.34 (+0.40%) ▲|NFLX76.60-0.17 (-0.22%) ▼|NKE37.17-0.93 (-2.45%) ▼|NOW133.49-0.75 (-0.56%) ▼|NVDA225.19-0.54 (-0.24%) ▼|ORCL162.35-0.17 (-0.10%) ▼|PEP137.42-1.03 (-0.74%) ▼|PFE27.63-0.17 (-0.61%) ▼|PG142.72-2.87 (-1.97%) ▼|PLTR170.35+0.05 (+0.03%) ▲|PM181.57-3.21 (-1.74%) ▼|QCOM179.87+5.78 (+3.32%) ▲|RTX198.29-0.55 (-0.28%) ▼|SBUX100.49-1.52 (-1.49%) ▼|SCHW107.04+0.17 (+0.16%) ▲|SO88.82-0.19 (-0.21%) ▼|SPG209.90+0.18 (+0.09%) ▲|T25.26-0.36 (-1.39%) ▼|TMO598.34-4.92 (-0.82%) ▼|TMUS181.01-0.68 (-0.37%) ▼|TSLA371.53+3.37 (+0.91%) ▲|TXN258.87-0.05 (-0.02%) ▼|UBER72.64-0.50 (-0.68%) ▼|UNH393.21-7.66 (-1.91%) ▼|UNP285.45-3.42 (-1.18%) ▼|UPS100.00-0.48 (-0.48%) ▼|USB62.07-0.44 (-0.70%) ▼|V367.71-1.11 (-0.30%) ▼|VZ49.86-0.54 (-1.07%) ▼|WFC88.22+0.25 (+0.28%) ▲|WMT105.36-0.70 (-0.66%) ▼|XOM164.76+4.05 (+2.52%) ▲|AAPL316.22-3.75 (-1.17%) ▼|ABBV248.78-7.68 (-2.99%) ▼|ABT105.04-0.54 (-0.51%) ▼|ACN179.19+0.15 (+0.08%) ▲|ADBE257.55+0.29 (+0.11%) ▲|AMAT473.00+0.21 (+0.04%) ▲|AMD514.91+9.17 (+1.81%) ▲|AMGN390.88-2.29 (-0.58%) ▼|AMT175.45-0.30 (-0.17%) ▼|AMZN252.84-4.13 (-1.61%) ▼|AVGO364.32-4.24 (-1.15%) ▼|AXP322.50-3.62 (-1.11%) ▼|BA211.19+0.36 (+0.17%) ▲|BAC61.83-0.56 (-0.90%) ▼|BKNG173.01-7.30 (-4.05%) ▼|BLK1,088.81-7.02 (-0.64%) ▼|BMY64.44-0.26 (-0.40%) ▼|BNY161.52-1.35 (-0.83%) ▼|BRK-B502.72-3.10 (-0.61%) ▼|C135.65-1.13 (-0.82%) ▼|CAT825.99+3.46 (+0.42%) ▲|CL87.45-0.96 (-1.09%) ▼|CMCSA26.06-0.27 (-1.03%) ▼|COF212.80-1.23 (-0.57%) ▼|COP136.61+1.56 (+1.16%) ▲|COST902.98-7.20 (-0.79%) ▼|CRM251.15+1.97 (+0.79%) ▲|CSCO109.96+0.79 (+0.72%) ▲|CVS96.34+0.25 (+0.26%) ▲|CVX213.35+3.35 (+1.60%) ▲|DE684.82+4.02 (+0.59%) ▲|DHR202.86-2.33 (-1.13%) ▼|DIS103.47-1.63 (-1.55%) ▼|DUK121.40+0.15 (+0.12%) ▲|EMR151.94-0.24 (-0.16%) ▼|FDX310.75-3.36 (-1.07%) ▼|GD356.58+0.03 (+0.01%) ▲|GE329.16-5.78 (-1.73%) ▼|GEV982.00+10.62 (+1.09%) ▲|GILD145.73-0.92 (-0.62%) ▼|GM85.56-0.22 (-0.26%) ▼|GOOG327.29-8.09 (-2.41%) ▼|GOOGL329.68-8.69 (-2.57%) ▼|GS1,017.52-19.16 (-1.85%) ▼|HD311.06-2.61 (-0.83%) ▼|HON208.03-0.21 (-0.10%) ▼|IBM235.36+3.25 (+1.40%) ▲|INTC103.88-0.59 (-0.56%) ▼|INTU320.05+1.12 (+0.35%) ▲|ISRG353.50+3.34 (+0.95%) ▲|JNJ268.79-0.39 (-0.14%) ▼|JPM351.52-2.03 (-0.57%) ▼|KO87.77-0.66 (-0.74%) ▼|LIN467.79-0.59 (-0.13%) ▼|LLY1,131.65+7.79 (+0.69%) ▲|LMT538.72+2.40 (+0.45%) ▲|LOW199.94-0.88 (-0.44%) ▼|LRCX320.58+0.16 (+0.05%) ▲|MA566.56-4.38 (-0.77%) ▼|MCD253.85-1.99 (-0.78%) ▼|MDLZ61.01-0.62 (-1.01%) ▼|MDT92.18-0.22 (-0.23%) ▼|META643.68+30.20 (+4.92%) ▲|MMM166.19-1.33 (-0.79%) ▼|MO67.57-0.61 (-0.89%) ▼|MRK148.14-0.34 (-0.23%) ▼|MS213.88-2.43 (-1.12%) ▼|MSFT492.73-1.22 (-0.25%) ▼|MU1,001.54+1.28 (+0.13%) ▲|NEE84.19+0.34 (+0.40%) ▲|NFLX76.60-0.17 (-0.22%) ▼|NKE37.17-0.93 (-2.45%) ▼|NOW133.49-0.75 (-0.56%) ▼|NVDA225.19-0.54 (-0.24%) ▼|ORCL162.35-0.17 (-0.10%) ▼|PEP137.42-1.03 (-0.74%) ▼|PFE27.63-0.17 (-0.61%) ▼|PG142.72-2.87 (-1.97%) ▼|PLTR170.35+0.05 (+0.03%) ▲|PM181.57-3.21 (-1.74%) ▼|QCOM179.87+5.78 (+3.32%) ▲|RTX198.29-0.55 (-0.28%) ▼|SBUX100.49-1.52 (-1.49%) ▼|SCHW107.04+0.17 (+0.16%) ▲|SO88.82-0.19 (-0.21%) ▼|SPG209.90+0.18 (+0.09%) ▲|T25.26-0.36 (-1.39%) ▼|TMO598.34-4.92 (-0.82%) ▼|TMUS181.01-0.68 (-0.37%) ▼|TSLA371.53+3.37 (+0.91%) ▲|TXN258.87-0.05 (-0.02%) ▼|UBER72.64-0.50 (-0.68%) ▼|UNH393.21-7.66 (-1.91%) ▼|UNP285.45-3.42 (-1.18%) ▼|UPS100.00-0.48 (-0.48%) ▼|USB62.07-0.44 (-0.70%) ▼|V367.71-1.11 (-0.30%) ▼|VZ49.86-0.54 (-1.07%) ▼|WFC88.22+0.25 (+0.28%) ▲|WMT105.36-0.70 (-0.66%) ▼|XOM164.76+4.05 (+2.52%) ▲|
22.5 C
New York
Wednesday, September 9, 2026

Tag: poster

newssourceFORcompanyinformationcontent1releasesmarket

Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin...

SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late-breaking poster presentations at the American Diabetes Association 85th Scientific Sessions, being held from June 20-23 in Chicago, IL.

Smart Insulin Tech Helps Pregnant Women with Type 1 Diabetes Maintain Target Blood Glucose Levels

Hybrid closed-loop technology effectively helped women stay in target glucose range for longer compared to standard of care CHICAGO, June 20, 2025 /PRNewswire/ -- A...

Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess...

Both subcutaneous and oral formulations will advance straight to phase 3 development based on completed clinical studies and feedback received from regulatory authorities1,2PLAINSBORO, N.J.,...

Cirius Therapeutics Announces Positive Data for MPC Inhibitor 0602K Alone and in Combination with Tirzepatide

MPC-inhibitor 0602K shows significant preservation of lean mass & increased muscle function combined with tirzepatide in pre-clinical DIO models0602K shows profound beneficial transformation of...

Neurocrine Biosciences Presents New Data Showing Significant Patient-Reported Improvements in Health-Related Quality of Life with INGREZZA® (valbenazine) Capsules in Older Adults with Tardive Dyskinesia

Data Add to Growing Body of Evidence Demonstrating Functional and Quality of Life Improvements in Patients Treated with INGREZZA for Tardive Dyskinesia Findings Presented at...

Theranica to Present Three Real-World Evidence Studies at AHS Scientific Meeting Highlighting the Impact of the Nerivio® REN Wearable on Migraine Treatment

Theranica is presenting three real-world evidence studies at the American Headache Society (AHS) 67th Annual Scientific Congress.

TOMY to Hold “TOMICA Expo 2025 in TAIWAN” to Experience World of TOMICA from June 28 (Sat) to September 14 (Sun), 2025 in Taiwan...

- TOMICA Expo Commemorative Model "Taiwan Taxi" to be Sold - TOKYO, June 19, 2025 /PRNewswire/ -- TOMY Company, Ltd., based in Katsushika Ward, Tokyo,...

Participation in “The 113th Congress of Japan Society of Aesthetic Surgery,” May 2025

～Record Participation for SBC Medical. 22 doctors Present Insights in Their Respective Fields～ 
～Record Participation for SBC Medical. 22 doctors Present Insights in Their Respective Fields～

NYSCC Suppliers’ Day 2025 Wraps with Record Attendance, Global Reach, and Unmatched Innovation

Ingredient & Formulation Trade Show & Conference Solidifies Its Position as the Premier Event for Beauty & Personal Care Product Development 
Ingredient & Formulation Trade Show & Conference Solidifies Its Position as the Premier Event for Beauty & Personal Care Product Development

EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL

ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that results from 13 studies of its core assets, including the novel drug olverembatinib (HQP1351) and the investigational EED inhibitor APG-5918, have been reported at the 2025 European Hematology Association (EHA) Annual Congress.

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia at EHA 2025

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib 
New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib

Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA’s 85th Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 12, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and...

Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses

-- Breadth of presentations, including one oral and two flash talks, showcase Blueprint Medicines' leadership role in advancing care for patients with systemic mastocytosis...

AACC, NSF Announce Winning Teams of 2025 Community College Innovation Challenge

Bergen Community College; Perimeter College at Georgia State University; and Dallas College took home winning titles following presentations of their STEM innovations to address real-world challenges WASHINGTON,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsPoster

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers